Skip to content

Anesthetic effect of ciprofol in patients undergoing hysteroscopic surgery

Anesthetic effect of ciprofol in patients undergoing hysteroscopic surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053768
Enrollment
Unknown
Registered
2021-11-29
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

control group:propofol

Sponsors

Lishui People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Females aged 18 to 70 years; 2. ASA grades are grades I to III; 3. 18 kg/m2 =10 and = 95% when inhaling air; SBP>=90 mmHg; DBP >= 60 mmHg; heart rate should be >=60 and <= 100 times/min; 5. Be able to understand the procedures and methods of this research, be willing to sign the informed consent form and strictly follow the clinical research protocol to complete this research.

Exclusion criteria

Exclusion criteria: 1. Those with contraindications to general anesthesia; 2. Those who plan to undergo general intravenous anesthesia and need to combine other anesthesia methods, such as inhalation anesthesia, spinal anesthesia, nerve block, etc.; 3. Associated with infectious heart diseases such as myocarditis or endocarditis, sepsis; 4. Patients with craniocerebral injury, possible intracranial hypertension, cerebral aneurysm, and history of cerebrovascular accident; 5. Acute heart failure, unstable angina pectoris, myocardial infarction within 6 months before screening, resting ECG heart rate = 2.5 times the upper limit of normal, TBIL >= 1.5 times the upper limit of normal), abnormal renal function (BUN or Urea >= 1.5 times the upper limit of normal, Cr > the upper limit of normal, or 28 times before surgery Dialysis treatment within the past few days), or those with obvious abnormal coagulation function (PT/APTT/TT higher than the upper limit of normal), anemia or thrombocytopenia (Hb = 160 mmHg, and/or diastolic blood pressure DBP >= 100 mmHg during the screening period); 8. Sitting systolic blood pressure SBP= 11.1 mmol/L during screening period, and/or random blood glucose >= 13.6 mmol/L); 10. History of drug and alcohol abuse within 2 years before the start of the screening period, and alcohol abuse is defined as regular drinking more than 14 times/week (1 time = 150 ml of wine or 360 ml of beer or 45 ml of spirits); 11. Subjects who are judged to have difficulty in airway management, the modified Markov score is grade IV; 12. Known or suspected allergic or contraindicated to various components of the study drug or other benzodiazepines, opioids, propofol, muscle relaxants, etc.; 13. Those who have participated in any clinical trial as subjects within 3 months before enrollment; 14. Other conditions judged by the investigator to be unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Respiratory depression;

Secondary

MeasureTime frame
incidence of injection pain;heart rate;time of loss of consciousness;spontaneous breathing recovery time;feel sick and vomit;wake up time;evaluation of Anesthesiologist's satisfaction;

Countries

China

Contacts

Public ContactWu Jimin

Lishui People's Hospital

15240143@qq.com+86 18957091906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026